Royal Bank Of Canada began coverage on shares of Immune Design Corp. (NASDAQ:IMDZ) in a report released on Thursday, MarketBeat reports. The brokerage issued an outperform rating and a $20.00 price target on the biotechnology company’s stock.

Other analysts have also issued reports about the stock. BidaskClub lowered shares of Immune Design Corp. from a strong-buy rating to a buy rating in a report on Saturday, August 5th. Zacks Investment Research upgraded shares of Immune Design Corp. from a sell rating to a hold rating in a report on Thursday, May 18th. ValuEngine upgraded shares of Immune Design Corp. from a strong sell rating to a sell rating in a report on Thursday, June 22nd. Jefferies Group LLC restated a buy rating and issued a $18.00 price objective on shares of Immune Design Corp. in a report on Wednesday, June 28th. Finally, Cowen and Company restated a buy rating on shares of Immune Design Corp. in a report on Tuesday, June 6th. One analyst has rated the stock with a hold rating and five have given a buy rating to the company’s stock. Immune Design Corp. has a consensus rating of Buy and an average price target of $16.33.

Shares of Immune Design Corp. (NASDAQ:IMDZ) opened at 9.35 on Thursday. The company’s market capitalization is $239.54 million. Immune Design Corp. has a 12 month low of $4.50 and a 12 month high of $13.05. The company has a 50-day moving average price of $9.69 and a 200-day moving average price of $7.90.

Immune Design Corp. (NASDAQ:IMDZ) last issued its quarterly earnings data on Wednesday, August 2nd. The biotechnology company reported ($0.54) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.65) by $0.11. Immune Design Corp. had a negative net margin of 324.33% and a negative return on equity of 59.14%. The business had revenue of $0.73 million during the quarter, compared to analyst estimates of $1.50 million. On average, equities analysts anticipate that Immune Design Corp. will post ($2.34) EPS for the current year.

ILLEGAL ACTIVITY NOTICE: “Royal Bank Of Canada Begins Coverage on Immune Design Corp. (IMDZ)” was originally reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this article on another website, it was copied illegally and republished in violation of U.S. & international trademark & copyright laws. The legal version of this article can be accessed at https://www.thecerbatgem.com/2017/09/17/royal-bank-of-canada-begins-coverage-on-immune-design-corp-imdz.html.

In related news, Director Lewis W. Coleman acquired 10,000 shares of the stock in a transaction on Monday, July 10th. The stock was acquired at an average cost of $9.00 per share, for a total transaction of $90,000.00. Following the completion of the acquisition, the director now directly owns 40,000 shares of the company’s stock, valued at approximately $360,000. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, Director Lewis W. Coleman acquired 8,000 shares of the stock in a transaction on Friday, July 7th. The stock was bought at an average price of $9.27 per share, with a total value of $74,160.00. Following the completion of the acquisition, the director now directly owns 40,000 shares of the company’s stock, valued at $370,800. The disclosure for this purchase can be found here. Insiders acquired 30,000 shares of company stock valued at $272,760 over the last 90 days. 42.90% of the stock is currently owned by company insiders.

A number of institutional investors and hedge funds have recently modified their holdings of IMDZ. Victory Capital Management Inc. lifted its holdings in shares of Immune Design Corp. by 2.1% during the second quarter. Victory Capital Management Inc. now owns 1,977,564 shares of the biotechnology company’s stock valued at $19,281,000 after purchasing an additional 40,010 shares during the last quarter. Franklin Resources Inc. lifted its holdings in shares of Immune Design Corp. by 2.7% during the second quarter. Franklin Resources Inc. now owns 760,253 shares of the biotechnology company’s stock valued at $7,412,000 after purchasing an additional 20,000 shares during the last quarter. JPMorgan Chase & Co. lifted its holdings in shares of Immune Design Corp. by 118.7% during the second quarter. JPMorgan Chase & Co. now owns 530,702 shares of the biotechnology company’s stock valued at $5,175,000 after purchasing an additional 288,009 shares during the last quarter. Vanguard Group Inc. lifted its holdings in shares of Immune Design Corp. by 37.9% during the second quarter. Vanguard Group Inc. now owns 524,999 shares of the biotechnology company’s stock valued at $5,118,000 after purchasing an additional 144,408 shares during the last quarter. Finally, FMR LLC lifted its holdings in shares of Immune Design Corp. by 0.4% during the first quarter. FMR LLC now owns 445,152 shares of the biotechnology company’s stock valued at $3,027,000 after purchasing an additional 1,699 shares during the last quarter. Institutional investors and hedge funds own 51.46% of the company’s stock.

Immune Design Corp. Company Profile

Immune Design Corp. is a clinical-stage immunotherapy company. The Company is focused on cancer with in vivo approaches designed to enable the body’s immune system to fight disease. The Company has engineered its technologies to activate the immune system’s natural ability to create tumor-specific cytotoxic T cells (CTLs) to fight cancer.

Receive News & Stock Ratings for Immune Design Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immune Design Corp. and related stocks with our FREE daily email newsletter.